Tahoe Therapeutics Releases Tahoe-100M Single-Cell Perturbation Atlas to Train Virtual Cell Models
November 11, 2026 • Source: BioSpace
Tahoe Therapeutics (formerly Vevo Therapeutics) released Tahoe-100M, the world's largest single-cell transcriptomic perturbation dataset comprising 100 million cells across 50 cancer models and 1,100 small-molecule drugs.
**Executive Summary (2026-11-11):** Tahoe Therapeutics (formerly Vevo Therapeutics) released Tahoe-100M, the world's largest single-cell transcriptomic perturbation dataset comprising 100 million cells across 50 cancer models and 1,100 small-molecule drugs. Source: BioSpace.
Technical Architecture & R&D Impact
Generated using its Mosaic in vivo and high-throughput single-cell barcoding platform, Tahoe-100M provides 50x more perturbation training data than prior public Perturb-seq compendia to train predictive virtual cell foundation models.
Enterprise Biopharma Procurement Takeaways
For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Launch category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.
Related Products
Published November 11, 2026
More NewsLast updated: November 11, 2026
